Beckerman Institutional LLC Grows Position in Pfizer Inc. (NYSE:PFE)

Beckerman Institutional LLC raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 27.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,538 shares of the biopharmaceutical company’s stock after purchasing an additional 3,540 shares during the quarter. Beckerman Institutional LLC’s holdings in Pfizer were worth $439,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Raab & Moskowitz Asset Management LLC lifted its holdings in shares of Pfizer by 10.2% in the fourth quarter. Raab & Moskowitz Asset Management LLC now owns 285,567 shares of the biopharmaceutical company’s stock worth $7,576,000 after buying an additional 26,433 shares in the last quarter. Van ECK Associates Corp lifted its holdings in shares of Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company’s stock worth $564,739,000 after buying an additional 4,726,549 shares in the last quarter. Harvey Capital Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter worth about $544,000. Kentucky Trust Co bought a new position in shares of Pfizer in the fourth quarter worth approximately $1,666,000. Finally, Gladstone Institutional Advisory LLC increased its position in shares of Pfizer by 9.0% in the fourth quarter. Gladstone Institutional Advisory LLC now owns 164,432 shares of the biopharmaceutical company’s stock worth $4,362,000 after purchasing an additional 13,587 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on PFE. Guggenheim restated a “buy” rating and issued a $33.00 price objective on shares of Pfizer in a research report on Monday. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Performance

NYSE:PFE opened at $25.46 on Thursday. The business has a 50 day moving average price of $26.28 and a 200-day moving average price of $27.65. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The firm has a market cap of $144.28 billion, a PE ratio of 18.06, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm posted $0.10 earnings per share. The firm’s revenue was up 24.7% on a year-over-year basis. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.76%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.